Evidence map›Paper›PMID 31885368›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Brain-Derived Neurotrophic Factor Alleviates Ropivacaine-Induced Neuronal Damage by Enhancing the Akt Signaling Pathway.

Yongyi Zhai, Yong Ma, Jingying Liu, Yulin Zhu, Kun Xie, Lingzhi Yu, Hao Zhang

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Yongyi ZhaiDepartment of Rehabilitation, Linzi District People's Hospital, Zibo, Shandong, China (mainland).
Yong MaDepartment of Anesthesiology, People's Liberation Army 970 Hospital, Yantai, Shandong, China (mainland).
Jingying LiuDepartment of Obstetrics, Yantaishan Hospital, Yantai, Shandong, China (mainland).
Yulin ZhuDepartment of Anesthesiology, Yantanshan Hospital, Yantai, Shandong, China (mainland).
Kun XieDepartment of Anesthesiology, The Second Hospital of Shandong University, Jinan, Shandong, China (mainland).
Lingzhi YuDepartment of Pain, Jinan Central Hospital affiliated to Shandong University, Jinan, Shandong, China (mainland).
Hao ZhangDepartment of Anesthesiology, People's Liberation Army 970 Hospital, Yantai, Shandong, China (mainland).
People's Liberation Army 401 Hospital · CNYantaishan Hospital · CNJinan Central Hospital · CNLinzi District People's Hospital · CNSecond Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Brain-derived neurotrophic factor (BDNF) is one of the neurotrophic factors that modulate critical metabolic activities, including apoptosis, proliferation, and differentiation modulation. Although numerous studies have focused on the damaging effects of BDNF on neurons, the underlying relationship between these effects remains unclear. In the present study, we investigated the protective effect of BDNF on neuronal injury induced by ropivacaine and assessed whether it is related to the Akt signaling pathway. MATERIAL AND METHODS Human neuroblastoma cell line SH-SY5Y cells were stimulated with ropivacaine at different concentrations to induce neuronal injury. MTT analysis, flow cytometry, immunohistochemistry, qRT-PCR, and Western blot were used to investigate the proliferation activity, apoptotic level, and expression of Akt, PCNA, Bax, Bcl-2, and cleaved caspase-3, collectively demonstrating the underlying regulatory mechanisms. RESULTS Compared with the control group, the morphological damage and proliferation inhibition of SH-SY5Y cells induced by ropivacaine were dose-dependent and time-dependent, accompanied by a significant decrease in Akt expression. We treated cells with BDNF or SC79, which is a selective cell-permeable small molecule Akt activator. The results showed that, compared to the ropivacaine group, the morphological damage of neurons was alleviated; cell proliferation activity was enhanced; apoptotic rate was reduced; PCNA, Bcl-2, and phosphorylated Akt expression levels were increased; and Bax and caspase-3 gene and protein expression were decreased. We were able to reverse these effects by administering API-2, an Akt inhibitor. CONCLUSIONS BDNF can alleviate ropivacaine-induced neuronal injury by activating Akt signaling pathway, consequently modulating the proliferation and apoptosis of neurons.

Indexed as

Signal TransductionApoptosisbcl-2-Associated X ProteinBrain-Derived Neurotrophic FactorCaspase 3Cell Line, TumorCell ProliferationCell ShapeHumansNeuronsProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-aktRNA, MessengerRopivacainebcl-2-Associated X ProteinBrain-Derived Neurotrophic FactorCaspase 3Proliferating Cell Nuclear AntigenProto-Oncogene Proteins c-aktRNA, MessengerRopivacaine

Identifiers

PMID31885368
PMCPMC6951110
OpenAlexW2998676943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.